Ivonescimab NMPA Approval Signals Breakthrough ...

By Rene Pretorius

May 2, 2025

Ivonescimab, a pioneering PD-1/VEGF bispecific antibody developed by Akeso, Inc., secured approval from China’s National Medical Products Administration (NMPA) on April 25, 2025, for first-line treatment of PD-L...

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.